中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

25 records (took 0.027 seconds)

    PRMT1 FOR TARGET GENES OF CANCER THERAPY AND DIAGNOSIS
    13.
    发明公开
    PRMT1 FOR TARGET GENES OF CANCER THERAPY AND DIAGNOSIS 有权
    PRMT1用于癌症治疗和诊断的靶基因

    公开(公告)号：EP2329044A1

    公开(公告)日：2011-06-08

    申请号：EP09809533.4

    申请日：2009-08-25

    Applicant: Oncotherapy Science, Inc.

    Inventor： NAKAMURA, Yusuke ,  HAMAMOTO, Ryuji ,  TOGASHI, Akira

    IPC: C12Q1/68 ,  C12N15/00

    CPC classification number: C12N15/1137 ,  C12N2310/14 ,  C12Q1/6886 ,  C12Q2600/136 ,  C12Q2600/154 ,  C12Q2600/158 ,  C12Y201/01125 ,  G01N33/57407 ,  G01N33/57484 ,  G01N2500/10

    Abstract: Objective methods for diagnosing a predisposition to developing cancer, particularly bladder cancer, gastric cancer, colorectal cancer, breast cancer, esophageal cancer, lung cancer, lymphoma, pancreatic cancer and testicular cancer, are described herein. In one embodiment, the diagnostic method involves determining an expression level of PRMT1 gene. The present invention further provides methods of screening for therapeutic agents useful in the treatment of PRMT1 associated disease, such as a cancer, e.g. bladder cancer, gastric cancer, colorectal cancer, breast cancer, esophageal cancer, lung cancer, lymphoma, pancreatic cancer and testicular cancer. The present invention further provides methods of inhibiting the cell growth and treating or alleviating symptoms of PRMT1 associated diseases. The present invention also features products, including double-stranded molecules and vectors encoding thereof as well as to compositions comprising them.

    Abstract translation: 本文描述了用于诊断癌症发生倾向的客观方法，特别是膀胱癌，胃癌，结肠直肠癌，乳腺癌，食道癌，肺癌，淋巴瘤，胰腺癌和睾丸癌。 在一个实施方案中，诊断方法涉及确定PRMT1基因的表达水平。 本发明进一步提供了筛选可用于治疗PRMT1相关疾病例如癌症的治疗剂的方法。 膀胱癌，胃癌，结肠直肠癌，乳腺癌，食道癌，肺癌，淋巴瘤，胰腺癌和睾丸癌。 本发明还提供了抑制细胞生长和治疗或缓解PRMT1相关疾病症状的方法。 本发明的特征还在于产物，包括双链分子和编码它们的载体以及包含它们的组合物。

    C12ORF48 AS A TARGET GENE FOR CANCER THERAPY AND DIAGNOSIS
    19.
    发明公开
    C12ORF48 AS A TARGET GENE FOR CANCER THERAPY AND DIAGNOSIS 审中-公开
    C12ORF48作为靶基因用于癌症治疗和诊断

    公开(公告)号：EP2352825A1

    公开(公告)日：2011-08-10

    申请号：EP09809511.0

    申请日：2009-08-21

    Applicant: Oncotherapy Science, Inc.

    Inventor： NAKAMURA, Yusuke ,  NAKAGAWA, Hidewaki ,  TOGASHI, Akira

    IPC: C12N15/09

    CPC classification number: C07K14/4748 ,  C12Q1/6886 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/57434 ,  G01N33/57438 ,  G01N33/57484 ,  G01N2500/10

    Abstract: Objective methods for diagnosing a predisposition to developing pancreatic cancer and prostate cancer, particularly pancreatic ductal adenocarcinoma (PDAC) and castration-resistant prostate cancer, are described herein. In one embodiment, the diagnostic method involves the step of determining an expression level of C12ORF48 using siRNAs targeting the C12ORF48 gene. The invention also features products such as siRNAs as well as to compositions containing them. The present invention further provides methods of screening for therapeutic agents useful in the treatment of C12ORF48 associated disease, such as a cancer, e.g. pancreatic cancer and prostate cancer, as well as methods of inhibiting the cell growth and treating or alleviating one or more disease symptoms. The invention also features products such as double stranded molecules, as well as vectors and compositions containing them.

Patent Agency Ranking